Erstellt von fchar99
Alnylam Pharmace. diskutieren
Alnylam Pharmace.
WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
351,60 €
1,59 %
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Bank of America Co. from $295.00 to $307.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Bank of America Co. from $307.00 to $314.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at TD Cowen from $282.00 to $371.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Barclays PLC from $295.00 to $329.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Raymond James from $275.00 to $298.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $296.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target lowered by analysts at Sanford C. Bernstein from $314.00 to $310.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Northrop Grumman Corp. diskutieren